绝经前女性因良性妇科疾病行双侧输卵管卵巢切除术后雌激素治疗的使用情况
该研究利用IBM Watson Health MarketScan研究数据库,纳入2008至2019年间18至50岁因良性指征行双侧输卵管卵巢切除术(BSO)的女性61,980例,分析雌激素治疗(ET)的使用及随访检查模式。结果显示64.5%(95% CI 64.1-64.9%)的女性接受了ET,术后36个月内ET使用率从2008年的峰值69.5%下降至2016年的58.2%,连续ET的中位持续时间为5.3个月,ET使用率随年龄增加而下降。结论认为过去十年间绝经前女性因良性妇科疾病行BSO后ET使用率大幅下降。
要点
- 因良性指征行BSO的绝经前女性中,64.5%(95% CI 64.1-64.9%)接受了ET。
- 术后36个月内ET使用率从2008年的69.5%降至2016年的58.2%。
- 连续ET的中位持续时间为5.3个月,且ET使用率随年龄增加而下降。
核心结论
- 过去十年间,因良性妇科疾病行BSO的绝经前女性中ET使用率大幅下降。
研究设计与样本
- 使用IBM Watson Health MarketScan研究数据库,识别2008至2019年间18至50岁因良性妇科疾病行BSO的女性,共61,980例。
- ET定义为BSO前6周至BSO后36个月内配取任何雌激素处方,并检查骨密度和血脂检测等随访模式。
主要发现
- 总体64.5%(95% CI 64.1-64.9%)的女性接受了ET。
- 术后36个月内ET使用率从2008年的峰值69.5%下降至2016年的58.2%。
- 连续ET的中位持续时间为5.3个月。
- 术后36个月ET累积使用率:18-29岁为79.1%(95% CI 76.9-81.1),30-34岁为75.9%(95% CI 74.5-77.3%),35-39岁为70.2%(95% CI 69.1-71.2%),40-44岁为66.1%(95% CI 65.3-66.9%),45-50岁为60.0%(95% CI 59.4-60.6%)。
- 多变量模型显示,手术时间较近和伴有内科合并症的女性接受ET的可能性较低,而年轻女性、持有Medicaid保险、居住于东北部以外地区及同期行子宫切除术的女性接受ET的可能性较高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the use of estrogen therapy (ET) and patterns of follow-up evaluation for sequelae of estrogen deprivation among women who were premenopausal who underwent bilateral salpingo-oophorectomy (BSO) for benign gynecologic diseases. METHODS: The IBM Watson Health MarketScan Research Databases were used to identify women between age 18 and 50 years who underwent BSO from 2008 to 2019. Estrogen therapy was defined as any prescription of estrogen filled from 6 weeks before BSO to 36 months after BSO. Patterns of follow-up testing including bone mineral density and lipid testing were examined. RESULTS: We identified a total of 61,980 women who underwent BSO for benign indications. Overall, 64.5% (95% CI 64.1-64.9%) of women received ET. The rate of ET use within 36 months of surgery declined from a peak of 69.5% in 2008 to 58.2% in 2016. The median duration of continuous ET was 5.3 months. Estrogen therapy use declined with increasing age. The cumulative rate of ET use at 36 months after surgery was 79.1% (95% CI 76.9-81.1) in those aged 18-29 years, 75.9% (95% CI 74.5-77.3%) in those aged 30-34 years, 70.2% (95% CI 69.1-71.2%) in those aged 35-39 years, 66.1% (95% CI 65.3-66.9%) in those aged 40-44 years, and 60.0% (95% CI 59.4-60.6%) in those aged 45-50 years. In a multivariable model, women who underwent surgery more recently and those with medical comorbidities were less likely to receive ET, whereas younger women, those with Medicaid insurance, those outside of the northeast, and those who underwent concurrent hysterectomy were more likely to receive ET. CONCLUSION: Estrogen therapy use in women who are premenopausal who underwent BSO for benign gynecologic diseases has declined substantially over the past decade.
引用
- Suzuki Y, Huang Y, Melamed A, et al. Use of Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal. Obstet Gynecol. 2022. PMID: 35576334. doi:10.1097/AOG.0000000000004762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。